United Therapeutics Cleared to Begin Pig-Heart Transplant Trials in Humans
Event summary
- FDA cleared United Therapeutics' Investigational New Drug application for the EXPRESS clinical trial of its UHeart™, a pig-derived heart with 10 gene edits.
- The initial cohort will include up to two participants, with safety and efficacy data reviewed before enrolling a second participant.
- The study is designed as a phase 1/2/3 trial to evaluate safety and efficacy without separate phases, with a 24-week post-transplant follow-up period.
- United Therapeutics aims to expand the study to support a Biologics License Application (BLA) submission if initial data is supportive.
The big picture
United Therapeutics' FDA clearance for the EXPRESS trial marks a significant step in the field of xenotransplantation, addressing the critical shortage of human hearts for transplant. The company's approach, leveraging gene-edited pig hearts, could reshape the treatment landscape for end-stage heart disease if successful. This trial is part of a broader industry trend towards innovative solutions to organ shortages, with potential implications for other solid organ transplants.
What we're watching
- Regulatory Milestones
- The pace at which the FDA reviews and potentially expands the EXPRESS trial will signal confidence in the UHeart's safety and efficacy.
- Clinical Execution
- Whether United Therapeutics can successfully enroll and retain participants in the initial cohort will be critical for the trial's progression.
- Market Impact
- How the success or failure of the UHeart trial could influence the broader xenotransplantation field and investor sentiment towards United Therapeutics.
Related topics